PITCH
20.5.2021 15:12:07 CEST | Business Wire | Press release
Pitch , the collaborative presentation platform for modern teams, today announced that it has raised an $85 million Series B funding round led by Lakestar and Tiger Global, and joined by existing Pitch investors Index Ventures and Thrive Capital.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005667/en/
Six months after launching to the public, the Series B investment comes at a time of significant growth and momentum for Pitch. To date, tens of thousands of teams have opened 125,000 workspaces on Pitch, including top companies like Intercom, Superhuman and Notion.
“Our mission at Pitch is to enable every team’s best thinking,” said Christian Reber, Founder & CEO of Pitch. “It’s been six months since we launched to the world, and tens of thousands of teams have already discovered how easy it is to create, collaborate on and deliver beautiful presentations on Pitch. We’re thrilled to have two world-class partners in Tiger Global and Lakestar onboard as we pursue our vision to build the first complete platform for presentations.”
A new kind of platform
To accelerate its momentum in the year ahead, Pitch plans to use the new funding to develop its core technology and product, grow its global team, and extend its software platform across the entire presentation workflow.
- A publishing and content ecosystem: Pitch is building a dedicated home for publishing and exchanging presentations and templates. In this new ecosystem, users will be able to discover content from top creators and brands, and publish their own work directly to public profile pages. In the upcoming weeks, Pitch will launch the first of these pages for a select group of creators, and will open up access to all users later this year.
- Advanced presentation analytics: Pitch is building new integrated solutions for users to better distribute presentations and monitor performance. Rolling out in multiple stages this summer, these new features will enable secure sharing and advanced analytics within Pitch, and will give users detailed insights into the reach and readership of a presentation, engagement levels on specific slides, and more.
- Narrative recording and playback: Pitch is building new ways to highlight, record, and play back presentations in any context. Designed for a more remote, asynchronous world of work, these tools will ensure presenters and recipients can engage across an expanded range of meeting formats and team workflows. These tools are currently in beta, and will be rolled out in stages to users in the coming months.
“The exciting vision that Christian and the team at Pitch have is beyond just being a superior alternative to legacy presentation software," said Stephen Nundy, Partner at Lakestar. "A reimagining of the entire workflow surrounding presentations is very much overdue, and when coupled with the ability to harness new data and media integrations, Pitch will lead the way in changing how stories are told. I’m very proud to be joining the board of a European company with its sights set on a truly global opportunity.”
“We are incredibly impressed by the quality of Pitch’s offering today and Christian’s vision for the future. Pitch will be a true productivity platform, and we are excited to become investors in this special company,” says John Curtius, Partner at Tiger Global.
Pitch offers both free and paid plans for teams of all sizes. With Pitch Pro, teams unlock access to unlimited storage, video uploads, version history, and advanced permissioning for $10 per member per month.
About Pitch
Pitch is the collaborative presentation software for modern teams. With a focus on real-time collaboration, smart workflows, and intuitive design features, Pitch makes it fast and delightful for teams to create and deliver beautiful presentations, and easy for anyone to find inspiration from templates crafted by experts. Tens of thousands of teams have made the switch to Pitch, including top brands like Intercom, Superhuman, and Notion. Founded in 2018 by the team behind Wunderlist, and powered by a team of over 100 thinkers, makers, and storytellers, Pitch has raised over $135 million to date. To learn more and create a free account, visit pitch.com
About Lakestar
Lakestar is one of Europe's leading venture capital firms investing in technology companies led by exceptional entrepreneurs. The team’s early investments included Skype, Spotify, Facebook and airbnb. Since raising a first fund in 2013, Lakestar manages an aggregated volume of over EUR 1bn across three early stage funds, and more recently a growth fund. The company has expanded and broadened its portfolio and holds investments in the likes of Opendoor, Oscar, GYG, Glovo, Sennder, Eigen, FiveAI, Revolut and Hometogo to name a few. Lakestar has presence in Berlin, Zurich and London. Lakestar helps companies to identify new markets and expand into them rapidly, with a focus on the US and Europe. The team advises and supports portfolio companies in business development, recruitment, technology and marketing. The investments range from early stage companies to those in their growth stage. Visit us on LinkedIn and our website.
About Tiger Global Management
Tiger Global Management is a leading global technology investment firm with over $60 billion under management. The firm focuses on private and public companies in the internet, software, and financial technology sectors. Since 2001, Tiger Global has invested in hundreds of companies across more than 30 countries, including investments ranging from Series A to pre-IPO. The firm aims to partner with dynamic entrepreneurs operating market-leading companies in its core focus areas. Tiger Global’s investments have included JD.com, UiPath, Stripe, Databricks, Bytedance, Snowflake, Facebook, Alibaba, Procore, Chime, Blend, Peloton, Attentive, LinkedIn, Flipkart, and Toast.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005667/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
